Introduction
============

Neuroblastoma is the most common childhood malignancy, accounting for 15% of pediatric tumor-related deaths [@B1], [@B2]. Neuroblastoma presents variable clinical outcomes from fatal progression to spontaneous differentiation and regression, however, underlying molecular mechanisms remain unclear. Despite tailored treatment approaches have been used for decades, long-term survival in high-risk patients is lower than 50% [@B3]. Thus, a better understanding of the mechanisms underlying neuroblastoma pathogenesis is essential to development of effective and novel therapies.

Neuroblastoma is highly heterogeneous and its etiology remains largely unknown. When compared to adult solid tumors, only a paucity of somatic gene mutations in neuroblastoma have been identified [@B1]. *MYCN* amplification is present in \~20% human neuroblastoma and is associated with a poor prognosis [@B2]. Overexpression of *MYCN* in neural crest is sufficient to cause neuroblastoma in transgenic mice, while knockdown of *MYCN* in neuroblastoma cells induces differentiation and apoptosis [@B4]-[@B7]. *ALK* mutations have been identified in familial and sporadic neuroblastoma, leading to increased or constitutively active *ALK* and increased neuroblastoma proliferation [@B8]-[@B11]. Activated *ALK* collaborates with *MYCN* in neuroblastoma pathogenesis by inhibiting sympatho-adrenal progenitor cell death [@B12]. Recent genome-wide association studies (GWAS) have identified a number of neuroblastoma susceptibility genes, including *LIN28B*,*LMO1* and *BARD1* [@B4], [@B13]. Overexpression of the RNA binding protein *LIN28B* has been observed in high-risk neuroblastoma [@B14]. *LIN28B* acts through repression of *let-7* miRNAs, resulting in increased *MYCN* and *AURKA* protein expression in neuroblastoma cells [@B14]. *AURKA* was a direct *let-7* target and *AURKA* stabilizes MYCN at the protein level [@B15]. Overexpression of *LIN28B* in transgenic mouse model induces neuroblastoma [@B14]. *LMO1* is an oncogene associated with high-risk neuroblastoma and it is required for neuroblastoma proliferation [@B16]. Overexpression of *LMO1* in zebrafish synergizes with *MYCN* to promote neuroblastoma development and metastasis [@B17].

Neuroblastoma is derived from sympatho-adrenal progenitors. Dysregulation of sympathetic developmental program has been implicated in neuroblastoma tumorigenesis [@B1], [@B18]. Early sympathetic neurogenesis is regulated by a network of transcription factors, such as *PHOX2B, MASH1, HAND2, GATA2/3, INSM1* and *ISL1* [@B19]. Mutations of *PHOX2B* have been found in \~80% hereditary neuroblastoma [@B1], [@B13], [@B19]-[@B21]. *GATA3* is overexpressed in neuroblastoma and plays an important role in neuroblastoma proliferation and differentiation [@B22]. Recently, a polymorphism within a *LMO1* superenhancer that preserves a consensus GATA factor binding site predisposes the individual to neuroblastoma [@B23]. *GATA3* knockdown leads to decreased *LMO1* expression and reduced neuroblastoma growth [@B23]. *INSM1* is expressed in sympatho-adrenal precursors and required for sympathetic proliferation and differentiation [@B24]. In *MYCN* amplified neuroblastoma cells, *MYCN* induces aberrant expression of *INSM1*, which in turn suppresses MYCN phosphorylation and degradation and facilitates oncogenesis of neuroblastoma [@B25]. Analysis of neuroblastoma superenhancers and associated regulatory factors has uncovered core transcriptional circuitries that define three types of neuroblastoma cell identity. Of these, a sympathetic noradrenergic identity is defined by a core transcriptional module including the *PHOX2B, GATA3* and *HAND2* [@B26].

LIM-homeodomain transcription factor *ISL1* is expressed in sympathetic neurons immediately after their differentiation and plays a crucial role in sympathetic neuron development [@B27]. *ISL1* directly or indirectly regulates distinct temporal gene expression programs required for sympathetic neuronal proliferation and differentiation [@B28], [@B29]. Notably, a number of genes modulated by ISL1 during early sympathetic neurogenesis are involved in neuroblastoma tumorigenesis, such as *ALK, LIN28B, LMO1, GATA3* and*PROX1* [@B28]. Expression of *ISL1* has been associated with neuroblastoma, especially undifferentiated neuroblastoma [@B21], [@B30], however, the role of *ISL1* in neuroblastoma remains unexplored. Here, we found *ISL1* plays a critical role in neuroblastoma pathogenesis, acting upstream of multiple neuroblastoma oncogenic pathways. ISL1 physically interacts with GATA3, and together they bind to and synergistically regulate genes essential for neuroblastoma proliferation and differentiation. In addition, *ISL1* and *MYCN* function in parallel to control common yet distinct gene regulatory programs in neuroblastoma.

Materials and Methods
=====================

Cell culture and treatment
--------------------------

SH-SY5Y and SK-N-BE(2) cell lines were gifted by Dr. Zhen Zhang\'s lab (Shanghai Pediatric Congenital Heart Disease Institute, Shanghai Children\'s Medical Center, School of Medicine, Shanghai Jiaotong University) [@B31], and authenticated by Cell Bank/Stem Cell Bank, The Committee of Type Culture Collection of Chinese Academy of Sciences. Cells cultured as described [@B32] in RPMI 1640 medium (GIBCO, ThermoFisher, MA, USA) with 10% heat-inactivated Fetal Bovine Serum (FBS) (GIBCO) and 100 U/ml of penicillin/streptomycin (GIBCO). To induce differentiation, cells were cultured in DMEM (GIBCO) with 1% FBS and retinoic acid (RA, Sigma-Aldrich, Merck, Darmstadt, Germany) at a final concentration of 1µm (SH-SY5Y) to 10µm (SK-N-BE(2)).

To assess cell proliferation, Click-iT™ EdU Alexa Fluor™ 594 Imaging Kit (C10339, Invitrogen, ThermoFisher, MA, USA) was used for EdU staining following manufactory\'s instruction. Percentage of EdU+ cells were counted and normalized to total DAPI+ cells. Results were obtained from five independent replicates, and representative figures were presented. For cell counting, cells from triplicate wells were counted six field per well, and six independent replicates were performed.

Colony formation assay was carried out as described [@B33]. Briefly, SH-SY5Y cells were added to the 6-well plates at 200 cells per well with 2 ml medium and cultured at 37°C for 2 weeks. Cells were fixed in 4% Paraformaldehyde (PFA), and stained with 0.1% Crystal Violet (C8470, Solarbio, Beijing, China). Total number of colonies per well were counted. Four independent replicates were performed.

To assess neurite outgrowth, cells were cultured with RA or DMSO for 3 days and fixed in 4% PFA. SH-SY5Y cells were stained with TUJ1 (ab18207, Abcam, MA, USA). Images were taken with Leica Microscopy and the length of longest neurite of individual cells was measured by Photoshop (three replicates, and around 100 cells (n) per group were analyzed).

Gene knockdown and overexpression
---------------------------------

For gene knockdown by shRNAs, the corresponding short hairpin RNAs (shRNAs) were cloned into pLKO.1 vector (Plasmid \# 10878, Addgene, MA, USA). Scramble shRNAs were used as control. For gene overexpression, the respective cDNAs were inserted into pcDNA3.1 (Invitrogen, ThermoFisher, MA, USA) or Fugw plasmids (Plasmid \# 14883, Addgene). For lentivirus packaging, HEK293FT cells were co-transfected with constructed shRNA plasmids and packaging plasmids using the Fugene HD transfection reagent (Roche, Basel, Switzerland) according to manufacturer\'s recommendations. Culture supernatants were collected 48 hours later and used to infect the target cells. 48 hours after infection, Puromycin (2.0 μg /ml) was added for selection. For*MYCN* and *EPAS1* knockdown with siRNAs, Lipofectamine RNAiMAX Transfection Reagent (3778030, Invitrogen) was used following the protocol. Sequence sets used for RNAi are listed in Table [S6](#SM0){ref-type="supplementary-material"}.

Transwell assay
---------------

Cells (2 × 10^4^cells) were starved in serum-free medium for 12 hours, and then placed on top chambers of 8 µm pore cell culture inserts (353097, FALCON, Corning, NY, USA) with serum-free medium. Lower chamber was filled with normal serum culture medium. After 24 hours, cells in the upper chamber were cleared with cotton swabs and remaining migrating cells were fixed and stained with 0.1% Crystal Violet (C8470, Solarbio, Beijing, China). Images were taken, and cells were counted. Data was presented as percentage of *ISL1* KD versus control migrating cells (migration index). Five repeats were performed.

In vivo tumorigenicity
----------------------

In vivo tumorigenic assays were performed using female NOD/SCID mice (NOD.CB17-Prkdc/NCrHsd, 8 weeks old purchased from SHANGHAI SLAC LABORATORY ANIMAL CO. LTD, Shanghai, China). Four mice per group were subcutaneously injected with 2× 10^7^ SH-SY5Y cells resuspended in 200 μl PBS into the left and right groin flank and injected mice were sacrificed at indicated time points. Tumor volume size was measured and calculated using the following equation: Volume = 0.5x length x width^2^. All animal experiments were performed according to the guidelines for the Care and Use of Laboratory Animals (Ministry of Health, China, 1998), and monitored by the Institutional Animal Care and Use Committee of Tongji University School of Medicine. Three independent repeats were performed.

Luciferase assay
----------------

Luciferase assay was performed with Dual-Luciferase® Reporter Assay System (Promega, WI, USA) following manufactory\'s instruction. Briefly, a 553 bp super enhancer fragment of *LMO1* (hg19, chr11:8255155-8255707) [@B23] was cloned into the upstream of the promoter-Luc+ transcriptional unit of pGL3-promoter Vector (E1761, Promega). HEK293T cells were grown in 24-well plates and transfected with 0.2 μg pGL3-*LMO1*-luc and 0.01 μg Renilla luciferase vector (pRL-TK; Promega), together with amount of pcDNA3.1-*ISL1* or *-GATA3* or empty pcDNA3.1 plasmid (control) as indicated. 48 hours after transfection, transfected HEK293T cells were harvest and lysed for luciferase assays. Three independent experiments were performed.

Western blot and immunoprecipitation (IP)
-----------------------------------------

For IP, HEK293T cells were transfected with plasmids encoding HA-ISL1 or Myc-GATA3. Neuroblastoma or transfected HEK293T cells were lysed with RIPA (10mM Tris-HCL, pH7.6, 1mM EGTA and EDTA, 0.1% SDS, 1% Triton X-100, 0.1% NA-Deoxycholate, 1× protease inhibitor cocktail (Roche Applied Science, IN, USA) and 1mM PMSF), cell lysates were subjected to immunoprecipitation using antibodies as indicated, and analyzed by Western Blot.

The following antibodies were used: anti-GATA3 (ab199428, Abcam), anti-ISL1 (ab109517, Abcam, MA, USA), anti-HA (ab9110, Abcam), rabbit normal IgG (Millipore, 12-370, Merck, Darmstadt, Germany), anti-Myc tag (ab32, Abcam) and anti-GAPDH (60004-1-Ig, Proteintech, IL, USA).

RNA-seq and q-PCR analyses
--------------------------

RNA-seq analysis was carried out as previously described [@B34]. All RNA-seq datasets were deposited into SRA database (<http://www.ncbi.nlm.nih.gov/SRA/>) under the accession code SRP159301. Briefly, cultured cells were collected, and total RNA was prepared using the RNeasy Mini kit (QIAGEN). RNA-seq libraries were constructed using SMARTer cDNA library construction kit (Clontech, Takara Bio, CA, USA) and sequenced on the BGISEQ-500 (BGI, Beijing, China). Significant expression of a transcript was considered if RPKM ≥ 1 in either one of the two conditions. Differentially expressed genes were identified with DEseq2, with a cutoff at a *p-*value \< 0.05 and \| log2 fold change *ISL1* KD mutant vs ctrl \| ≥ 0.5. GSEA (Gene Set Enrichment Analysis) and GO enrichment analysis were performed with GSEA software and DAVID Functional Annotation Tools, respectively.

RNAs were reverse-transcribed with SuperScript II First-Strand Synthesis System (Invitrogen, ThermoFisher, MA, USA). qPCR analyses were performed using SYBR green detection (ABI, ThermoFisher, MA, USA) with primers listed in Table [S7](#SM0){ref-type="supplementary-material"}.

ChIP-seq, data analysis and ChIP-qPCR
-------------------------------------

ChIP was carried out following protocol as described [@B34]. All ChIP-seq datasets were deposited into SRA database under the accession code SRP159115. Briefly, 2x10^6^ cultured cells were cross-linked with 1% formaldehyde and lysed with RIPA buffer (see in western blot). Chromatin was sheared with sonication to 100-400 bp DNA fragments. ISL1-bound DNA was immunoprecipitated by anti-ISL1 antibody (ab109517, Abcam, MA, USA). After reverse cross-linking, the DNA was purified using the Qiagen PCR purification kit (Qiagen). ChIP sequencing libraries were generated and amplified for 15 cycles. 225-375 bp DNA fragments were gel-purified and sequenced with HI-seq 2500 (Illumina). Reads alignment to human genome assembly (NCBI38/hg19) was performed with Bowtie2. Binding peaks were called using HOMER with findPeaks and annotated using annotatePeaks.pl. Genome-wide distribution of ISL1 ChIP-Seq peaks were mapped according to their nearest downstream genes using cis-regulatory element annotation system, promoter areas include 1 kb upstream and 100 bp downstream of the transcription start site (TSS). Motif analysis for *ISL1* was performed using findGenomeMotif.pl. For the visualization of ChIP-seq data, the Integrative Genome Viewer IGV 2.3 was used (<http://www.broadinstitute.org/igv/>). GO analysis was performed with DAVID Functional Annotation software.

ChIP-qPCR was performed using ISL1 ChIP-DNA and IgG ChIP-DNA as templets and primers listed in Table [S7](#SM0){ref-type="supplementary-material"}. Data were normalized to the negative controls with primers to sequences that are adjacent (\>1-5 kb) to ISL1 binding regions but do not contain ISL1 binding motifs. At least three independent samples were analyzed.

In silico analysis, referenced data and data accessibility
----------------------------------------------------------

Neale Multi-cancer study [@B35] and Albino Neuroblastic-Tumor study [@B36] were obtained from Oncomine.org. Datasets of *ISL1* expression and DNA methylation in 1457 cancer cell lines were obtained from Cancer Cell Line Encyclopedia (<https://portals.broadinstitute.org/ccle>). Datasets of *ISL1* expression in poorly differentiated neuroblastomas and more differentiated neuroblastomas were obtained from Bourdeaut\'s study [@B30]. The ChIP-seq datasets for H3K4me1 and H3K27ac in SH-SY5Y cells can be accessed from GEO database under accession number GSM2120705 and GSM 2120706, respectively [@B37]. The ChIP-seq datasets for *GATA3* in SH-SY5Y cells can be accessed from GSM1602667 [@B23]. RNA-seq and ChIP-seq datasets of this study can be accessed from the SRA database under the accession number SRP159301 (RNA-seq) and SRP159115 (ChIP-seq).

Statistical analysis
--------------------

Data are expressed as mean ± SD. For 2-group comparisons, data were analyzed with 2-tailed t-test Statistical significances is considered if a *p*-value \< 0.05. Experiments were repeated independently three times or more.

Results
=======

Inverse correlation of *ISL1* expression and the differentiation grade of neuroblastoma
---------------------------------------------------------------------------------------

*ISL1* is one of the most sensitive markers overexpressed in neuroblastoma, especially in poorly differentiated ones [@B21], [@B30], however its role in neuroblastoma oncogenesis remains unexplored. We first analyzed *ISL1* expression in various cancer types using previously published datasets. Neale Multi-cancer study [@B35] obtained through Oncomine.org revealed that among human tumors analyzed, *ISL1* was most highly expressed in neuroblastoma (Figure [S1](#SM0){ref-type="supplementary-material"}A). Data from CCLE database (<https://portals.broadinstitute.org/ccle>) also demonstrated that, among 1457 neoplasm cell lines, the highest level of *ISL1* expression was observed in neuroblastoma (Figure [S1](#SM0){ref-type="supplementary-material"}B). Consistent with its higher level of expression, whole-genome DNA methylation profiling revealed the lowest methylation levels in the gene body of *ISL1* in neuroblastoma (Figure [S1](#SM0){ref-type="supplementary-material"}C). The dataset of Albino Neuroblastic-Tumor study [@B36] from Oncomine.org showed that, among 19 neuroblastic tumors expression of *ISL1* was significantly elevated in neuroblastoma compared with other two differentiated neuroblastic tumors (ganglioneuroblastoma and ganglioneuroma) (Figure [S1](#SM0){ref-type="supplementary-material"}D). Furthermore, analysis of another published neuroblastomas gene expression microarray dataset [@B30] revealed that *ISL1* expression was markedly increased in poorly differentiated neuroblastomas compared to more differentiated neuroblastomas (Figure [S1](#SM0){ref-type="supplementary-material"}E). Together, there data demonstrated that *ISL1* is upregulated in neuroblastoma and its expression level is inversely correlated with the differentiation grade of neuroblastoma.

Knockdown of *ISL1* results in inhibition of neuroblastoma growth
-----------------------------------------------------------------

To study the role of *ISL1* in neuroblastoma, we silenced *ISL1* expression in neuroblastoma cells using two different shRNAs against *ISL1* (sh*ISL1-1* and sh *ISL1-2*). Effective knockdown (KD) of *ISL1* expression was similarly observed in both SH-SY5Y (*MYCN* non-amplified) and SK-N-BE(2) (*MYCN*-amplified) neuroblastoma cell lines as confirmed by qRT-PCR and Western blot analyses (Figure [1](#F1){ref-type="fig"}A, B, Figure [S2](#SM0){ref-type="supplementary-material"}A-S2C). Knockdown of *ISL1* resulted in significant inhibition of cell expansion in both SH-SY5Y and SK-N-BE(2) neuroblastoma cell culture (Figure [1](#F1){ref-type="fig"}C, D). EdU staining and flow cytometric cell counting showed that the percentage of EdU-labeled cells was significantly decreased in *ISL1* KD neuroblastoma cells compared to controls (Figure [1](#F1){ref-type="fig"}E-G). In addition, *ISL1* downregulation suppressed colony formation of SH-SY5Y neuroblastoma cells (Figure [1](#F1){ref-type="fig"}H, I). To further assess whether *ISL1* knockdown could suppress tumor growth in vivo, we did tumor formation assays with *ISL1* KD and control SH-SY5Y neuroblastoma cells using a SCID mouse xenograft model. *ISL1* knockdown significantly inhibited tumor growth rate and reduced the volumes of *ISL1* KD tumors compared to controls (Figure [1](#F1){ref-type="fig"}J, K).

RNA-seq analysis revealed an important role of *ISL1* in promoting cell cycle-associated gene expression but repressing differentiation-associated gene expression in neuroblastoma
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate potential downstream genes of *ISL1* in neuroblastoma, we performed RNA-seq analysis on *ISL1* KD (sh*ISL1-1*) and control SH-SY5Y cells. Of 16,563 genes expressed at significant level in SH-SY5Y cells, transcripts for 935 genes were downregulated, and 673 were upregulated in *ISL1* KD SH-SY5Y cells (\|log2 Fold Change (*ISL1* KD vs. Ctrl) \| ≥ 0.5, p \< 0.05) (Figure [2](#F2){ref-type="fig"}A, Table [S1](#SM0){ref-type="supplementary-material"}). Gene ontology (GO) analysis revealed that the top GO terms for downregulated genes in *ISL1* KD SH-SY5Y cells were highly enriched in the cell cycle (Figure [2](#F2){ref-type="fig"}B).

For upregulated genes, categories including cell adhesion, signal transduction, synapse assembly, apoptosis and DNA damage response were overrepresented (Figure [2](#F2){ref-type="fig"}C). Gene Set Enrichment Analysis (GSEA) showed significantly downregulated gene sets enriched in the proliferation, DNA replication and mitotic nuclear division (Figure [2](#F2){ref-type="fig"}D-F). We confirmed by qRT-PCR alterations in expression of selected genes that could contribute to the observed phenotypes and have been shown to be involved in neuroblastoma oncogenesis. Those included genes involved in the cell cycle (*MKI67, E2F1, CENPF, BRCA1, BARD1, CDKN1A, CCNE1, CDCA4, AURKA*), gene expression regulation (*LMO1, LIN28B, CTBP2, MYB*) and extracellular matrix (ECM) and adhesion (*LOX, LUM, MMP2*) (Figure [2](#F2){ref-type="fig"}G). Expression of *GATA3*, a direct target of *ISL1* downregulated in *Isl1*-deficient sympathetic neurons [@B28], was not altered in *ISL1* KD SH-SY5Y cells (Figure [2](#F2){ref-type="fig"}G, Table [S1](#SM0){ref-type="supplementary-material"}). Retinoic acid (RA) can repress proliferation but induce differentiation of neuroblastoma cells and is widely used in neuroblastoma therapy. In *ISL1* KD neuroblastoma we observed increased expression of genes involved in RA signaling pathway (*RXRA*, *RORA*, *RARA* and *EPAS1* [@B38], [@B39]) and sympathetic neuronal differentiation (*RET, VIP, SYT4, SPRY1*) (Figure [2](#F2){ref-type="fig"}H), suggesting an increased neuronal differentiation and responsiveness of *ISL1* KD neuroblastoma cells to RA signaling. Consistent with this observation, we found significantly enhanced neurite outgrowth in *ISL1* KD SH-SY5Y cells compared with control cells in the presence of RA, although no significant difference was observed between *ISL1* KD and control SH-SY5Y cells in the absence of RA (Figure [2](#F2){ref-type="fig"}I-M). Furthermore, we observed significantly reduced migration of *ISL1* KD neuroblastoma cells compared to controls, consistent with reduced expression of genes involved in tumor cell microenvironment and metastasis (*MYB*, *LOX*, *LUM*, *CTBP2* and *MMP2*) in *ISL1* KD neuroblastoma cells (Figure [2](#F2){ref-type="fig"}N-P).

*ISL1* directly regulates genes essential for neuroblastoma pathogenesis
------------------------------------------------------------------------

To uncover direct targets of *ISL1* that could account for its role in neuroblastoma, we performed ChIP-seq analysis on SH-SY5Y cells using ISL1 antibody. Our analyses uncovered 8715 significant binding peaks for ISL1, mainly (89%) located at intergenic or intronic regions (Figure [3](#F3){ref-type="fig"}A, Table [S2](#SM0){ref-type="supplementary-material"}). HOMER motif analysis revealed that, besides ISL1 binding site, ISL1-bound regions also harbored conserved binding motifs for PHOX2A, GATA3, and other GATA and homeobox factors, suggesting that transcription factors from homeodomain and GATA families may collaborate with ISL1 to regulate neuroblastoma gene expression programs (Figure [3](#F3){ref-type="fig"}B, Table [S3](#SM0){ref-type="supplementary-material"}). Functional annotation according to the nearest TSS revealed 3602 ISL1 targets, including those related to heart and neuron development, consistent with the role of*ISL1* in heart and nervous system morphogenesis (Figure [3](#F3){ref-type="fig"}C). Intersection of ChIP-seq and RNA-seq datasets for *ISL1* KD and control SH-SY5Y cells uncovered 389 direct targets of *ISL1* downregulated (203) or upregulated (186) in *ISL1* KD neuroblastoma (Figure [3](#F3){ref-type="fig"}D). GO analysis showed that the downregulated targets of *ISL1* were highly enriched in categories, including DNA replication, microtubule, centriole replication and mitotic cell cycle (Figure [3](#F3){ref-type="fig"}E). Categories of upregulated genes included intracellular signal transduction, cell adhesion and cerebral cortex development (Figure [3](#F3){ref-type="fig"}F). In addition, we used published ChIP-seq histone modification datasets [@B37] to examine the chromatin state of ISL1-bound enhancers of selected genes involved in neuroblastoma pathogenesis, including *LMO1, RARA, EPAS1, CTBP2, CDKN1A* and *MYB* (Figure [3](#F3){ref-type="fig"}G). Integrative Genomics Viewer (IGV) showed that these ISL1 bound regions were co-modified by H3K27ac and H3K4me1, markers of active enhancer [@B40], suggesting these ISL1-bound enhancers are transcriptionally active in neuroblastoma.

*LMO1* is a direct downstream target of *ISL1*, partially accounting for the reduced proliferation in *ISL1* KD neuroblastoma
-----------------------------------------------------------------------------------------------------------------------------

Notably,*LMO1* is a neuroblastoma oncogene required for neuroblastoma proliferation and metastasis [@B16], [@B17], [@B23]. Previous study has showed that ISL1 can bind to the *LMO1* super-enhancer in mouse sympathetic neurons and is required for *LMO1* expression [@B28]. Our *ISL1* ChIP-seq data in SH-SY5Y cells revealed three ISL1-bound, active enhancer regions marked by H3K27ac and H3K4me1 (P1, P2 and P3) (Figure [3](#F3){ref-type="fig"}G). Of these enhancers, P2 region was at the first intron of *LMO1* across rs2168101, which is the *LMO1* superenhancer in human neuroblastoma (Figure [3](#F3){ref-type="fig"}G). ChIP-qPCR analysis confirmed binding of ISL1 at these enhancer regions, with the highest affinity of ISL1 binding observed at P2 region (Figure [4](#F4){ref-type="fig"}A). We carried out dual luciferase assay to measure the effect of ISL1 binding on *LMO1* enhancer activity. Luciferase activity of reporter constructs with the P2 enhancer of *LMO1* was significantly increased when co-transfected with increased concentration of construct expressing ISL1 protein (Figure [4](#F4){ref-type="fig"}B).

To test whether*ISL1* regulates *LMO1* to promote cell proliferation, we knocked down *ISL1* in SH-SY5Y cells and co-transfected with the plasmid expressing *LMO1* (sh*ISL1* + *LMO1*) or mock plasmid (sh*ISL1*). The transfected cells were cultured for 5 days and counted every day. EdU was added 3 hours before harvesting. We observed that the total number of cells and the percentage of EdU-positive cells were significantly increased in sh*ISL1* + *LMO1* transfected cells compared to sh*ISL1* + mock cells, although not to the extent of control cells (control shRNA and mock transfected) (Figure [4](#F4){ref-type="fig"}C-E). In addition, Q-PCR analysis revealed that *LMO1* re-expression significantly restored expression of the cell-cycle genes that were downregulated by *ISL1* knockdown, such as *MKI67*, *PCNA*, *CENPF* and *BRCA1* (Figure [4](#F4){ref-type="fig"}F). These data suggested that *ISL1* regulated neuroblastoma proliferation in part by directly controlling *LMO1* expression.

Studies have revealed conflicting roles of *EPAS1* in regulating neuroblastoma growth. RA plus 5-AZA treatment induced *EPAS1* upregulation and neuroblastoma differentiation, and inhibition of *EPAS1* diminished this differentiation effect [@B38]. On the other hand, inhibition of *EPAS1* combined with RA treatment has been also shown to enhance differentiation of neuroblastoma cells into glial cells [@B39]. We found that concomitant knockdown of *EPAS1* in *ISL1* KD neuroblastoma is insufficient to reverse phenotypes and changes in gene expression caused by *ISL1* KD (Figure [S3](#SM0){ref-type="supplementary-material"}).

*ISL1* and *GATA3* synergistically regulate downstream genes in neuroblastoma
-----------------------------------------------------------------------------

Previous studies have shown that GATA3 directly binds to the super enhancer of*LMO1* driving its expression and plays an essential role in sympathetic neurogenesis and neuroblastoma tumorigenesis [@B23], [@B28]. HOMER motif analyses of our ISL1 ChIP-seq datasets in both sympathetic neurons [@B28] and neuroblastoma cells (Figure [3](#F3){ref-type="fig"}B) suggested that GATA3 may act as a collaborative factor with ISL1 to regulate downstream genes. Comparison of ChIP-seq datasets for *GATA3* [@B23] and *ISL1* revealed substantial genome-wide co-occupancy of GATA3 and ISL1 at their binding regions (Figure [5](#F5){ref-type="fig"}A, B). A total of 2398 *ISL1* target genes, approximately two thirds of*ISL1* target genes, are potentially co-regulated by *GATA3* and *ISL1* (Figure [5](#F5){ref-type="fig"}C, Table [S4](#SM0){ref-type="supplementary-material"}). Overlay of the common target genes of *ISL1* and *GATA3* with genes differentially expressed in *ISL1* KD neuroblastoma cells revealed 213 common target genes down (111) or up (102) regulated in *ISL1* KD neuroblastoma (Figure [5](#F5){ref-type="fig"}C). GO analysis of these common target genes dysregulated in *ISL1* KD neuroblastoma revealed that the upregulated target genes were mainly associated with cell signaling, while the downregulated target genes were associated with neurite outgrowth, DNA replication and centriole assembly (Figure [5](#F5){ref-type="fig"}D). Integrative Genomics Viewer showed that co-occupancy of enhancers of selected genes (*CTBP2, EPAS1, CDKN1A* and *LMO1*) by*ISL1* and *GATA3* (Figure [5](#F5){ref-type="fig"}E). Furthermore, Q-PCR analysis revealed that knockdown of *GATA3* in SH-SY5Y cells led to altered expression of ISL1 target genes, although expression of *ISL1* itself was unchanged (Figure [5](#F5){ref-type="fig"}F).

To test whether*ISL1* and *GATA3* synergistically regulate their target gene expression, we performed *LMO1* super enhancer luciferase assay in 293T cells in the presence of *ISL1* and/or *GATA3*. Compared to mock transfected cells, significantly increased luciferase activity was observed in cells transfected with *ISL1* or *GATA3*. A further significantly enhanced luciferase activity was observed in cells co-transfected with *ISL1* and *GATA3*, compared to *ISL1* and *GATA3* alone (Figure [5](#F5){ref-type="fig"}G). To test whether *ISL1* and *GATA3* are sufficient to induce ectopic*LMO1* expression in 293T cells, in which the expression of *ISL1*,*GATA3* and *LMO1* is barely detectable. Transfection of 293T cells with *ISL1* slightly but significantly induced endogenous *LMO1* mRNA expression compared to mock transfected cells (Figure [5](#F5){ref-type="fig"}H). Although *GATA3* alone couldn\'t induce *LMO1* expression, co-transfection of*ISL1* and *GATA3* further significantly induced *LMO1* expression compared to *ISL1* alone (Figure [5](#F5){ref-type="fig"}H).

To further examine whether ISL1 and GATA3 are mutually dependent in their binding and activation of their target genes, we knocked down *ISL1* in SH-SY5Y cells and examined GATA3 binding to enhancers of selected genes (*EPAS1, LMO1* and *CTBP2*), and vice versa. ChIP-qPCR revealed that knockdown of *ISL1* resulted in significantly reduced GATA3 binding at those enhancers (Figure [5](#F5){ref-type="fig"}I). Interestingly however, binding of ISL1 at those enhancers was not significantly compromised by *GATA3* knockdown (Figure [5](#F5){ref-type="fig"}J), consistent with the inability of *GATA3* alone to promote *LMO1* expression in 293T cells. Although binding of ISL1 to the common target genes might be less dependent on *GATA3*, yet robust target gene activation requires both *GATA3* and *ISL1* (Figure [5](#F5){ref-type="fig"}G, H).

To examine whether ISL1 and GATA3 physically interact with each other to regulate target gene expression, we co-transfected 293T cells with HA-tagged ISL1 and Myc-tagged GATA3 expressing plasmids and performed co-immunoprecipitation using anti-HA antibody. We observed specific binding of ISL1 and GATA3 in HA-ISL1 and Myc-GATA3 co-transfected cells, but not in cells transfected with HA-ISL1 alone (Figure [S4](#SM0){ref-type="supplementary-material"}A, and arrow). To detect the interaction of endogenous ISL1 and GATA3, SH-SY5Y cell lysates were immunoprecipitated with anti-ISL1 antibody and Western blot using anti-GATA3 antibody was performed. Results revealed that ISL1 physically binds to GATA3 in neuroblastoma cells (Figure [S4](#SM0){ref-type="supplementary-material"}B, arrow).

*ISL1* and *MYCN* act in parallel to regulate common yet distinct oncogenic pathways in neuroblastoma
-----------------------------------------------------------------------------------------------------

*MYCN* amplification is common in human neuroblastoma that confers resistance to RA therapy [@B41]. To investigate the effect of *MYCN*-amplification on *ISL1*\'s function and possible epistatic interaction between *ISL1* and *MYCN*, we used a *MYCN*-amplified neuroblastoma cell line SK-N-BE(2) that, upon *MYCN* knockdown or RA treatment, will efficiently differentiate into neuron-like cells with extensive neurite outgrowth [@B42]-[@B45]. We found that expression of *MYCN* and its known target genes [@B41], [@B46]-[@B48] involved in neuronal and neuroblastoma differentiation, such as *p53, ASCL1* and *LMO4*, was not altered by*ISL1* knockdown in SK-N-BE(2) and SH-SY5Y neuroblastoma cells (Figure [6](#F6){ref-type="fig"}A, Table [S1](#SM0){ref-type="supplementary-material"}). Conversely, expression of *ISL1* and its key downstream genes *LMO1* and *LIN28B* was not significantly altered by *MYCN* knockdown (Figure [6](#F6){ref-type="fig"}B) (FC ≥ 1.5, p-value \< 0.05). Similar to that observed in SH-SY5Y cells, knockdown of *ISL1* in *MYCN*-amplified SK-N-BE(2) cells led to downregulation of *LMO1* and*LIN28B*, but unaltered *GATA3* expression (Figure [6](#F6){ref-type="fig"}A, Figure [2](#F2){ref-type="fig"}G). However, expression of some of cell cycle-related genes (e.g. *PCNA, BARD1* and *CDKN1A*) and genes of RA pathway was not altered, or altered to a lesser extent by *ISL1* knockdown in SK-N-BE(2) cells compared to SH-SY5Y cells (FC ≥ 1.5, *p-*value \< 0.05) (Figure [6](#F6){ref-type="fig"}A). On the other hand, knockdown of *MYCN* in SK-N-BE(2) cells resulted in altered expression of cell cycle-related genes (*CCNE1, AURKA, PCNA, BARD1* and *CDKN1A*), comparable to that observed in *ISL1* KD SH-SY5Y cells (Figure [6](#F6){ref-type="fig"}B). However, expression of genes of RA pathway in *MYCN* KD SK-N-BE(2) cells was not significantly increased (*RORA, RARA* and *EPAS1*) or was significantly decreased (*RXRA*) (Figure [6](#F6){ref-type="fig"}B).

Consistent with these findings, we observed significantly decreased proliferation in *ISL1* KD SK-N-BE(2) cells and a more pronounced decrease in proliferation in *MYCN* KD cells (Figure [6](#F6){ref-type="fig"}C-E, G). Double knockdown of *MYCN* and *ISL1* in SK-N-BE(2) cells led to a further significant decrease in cell proliferation, compared to single *ISL1* or *MYCN* knockdown (Figure [6](#F6){ref-type="fig"}C-G).

Similar to those in SH-SY5Y cells, knockdown of *ISL1* was unable to induce spontaneous neurite outgrowth in SK-N-BE(2) cells in the absence of RA. In contrast, *ISL1* KD failed to enhance RA treatment-induced neurite outgrowth (Figure [6](#F6){ref-type="fig"}H-K, P). We observed significantly increased neurite outgrowth in *MYCN* KD SK-N-BE(2) cells that was further enhanced by RA treatment (Figure [6](#F6){ref-type="fig"}L, M, P). This observation is consistent with previous studies [@B42]-[@B44], but in contrast to the rather subtle changes in mRNA expression of RA receptors in *MYCN* KD SK-N-BE(2) cells. Concomitant knockdown of *ISL1* and *MYCN* resulted in increased neurite outgrowth comparable to the single *MYCN* knockdown without RA treatment (Figure [6](#F6){ref-type="fig"}H, L, N, P). However, neurite outgrowth of SK-N-BE(2) cells with *ISL1*/*MYCN* double knockdown was further enhanced by RA treatment compared to RA untreated cells, or *MYCN* KD cells treated with RA (Figure [6](#F6){ref-type="fig"}M-P). These results suggested that neurite outgrowth is redundantly controlled by *MYCN* and *ISL1*, and *MYCN* control neurite outgrowth by RA-dependent and -independent pathways (Figure [6](#F6){ref-type="fig"}Q).

Consistent with our observation, intersection of 1608 differentially expressed genes (DEGs) in *ISL1* KD neuroblastoma and 2124 *MYCN* correlated genes from Hsu\'s study [@B48] identified 309 commonly regulated genes by *ISL1* and *MYCN* (Figure [S5](#SM0){ref-type="supplementary-material"}A, Table [S5](#SM0){ref-type="supplementary-material"}). GO analysis of these common genes revealed that top 10 overrepresented categories were all cell cycle related (Figure [S5](#SM0){ref-type="supplementary-material"}B, Table [S5](#SM0){ref-type="supplementary-material"}). By intersection of 389 *ISL1* direct targets identified in this study and 874 *MYCN* direct targets from Hsu\'s study [@B48], we found only 29 common direct targets, mainly associated signal transduction and cell division (Figure [S5](#SM0){ref-type="supplementary-material"}A, C, Table [S5](#SM0){ref-type="supplementary-material"}).

Discussion
==========

Here we reported a critical role for *ISL1* in neuroblastoma, and knockdown of *ISL1* in neuroblastoma results in reduced proliferation, but enhanced differentiation in response to RA treatment. *ISL1* and *GATA3* synergistically regulate multiple neuroblastoma oncogenic genes and pathways. In addition, our study revealed an epistatic relationship between *ISL1* and *MYCN* in the control of neuroblastoma pathogenesis, and *ISL1* and *MYCN* act in parallel to regulate common yet distinct pathways driving neuroblastoma pathogenesis (Figure [6](#F6){ref-type="fig"}Q).

Neuroblastoma arises from transformation of sympatho-adrenal progenitors due to impaired progenitor terminal differentiation. Dysfunction of early sympathetic developmental gene program has been shown to cause sympathetic neurogenesis defects and neuroblastoma [@B1], [@B18]. Our previous studies have uncovered a critical role of *ISL1* in sympathetic neurogenesis and implicated *ISL1* as a potential candidate gene involved in neuroblastoma [@B28], [@B29]. *ISL1* is overexpressed in all human neuroblastoma tumors and cell lines, and its expression is inversely correlated to neuroblastoma differentiation state.

Our ChIP-seq and RNA-seq analyses of *ISL1* KD SH-SY5Y neuroblastoma cells revealed a complex regulatory network downstream of *ISL1* that orchestrates neuroblastoma oncogenesis. Similar to its role in sympathetic neurogenesis,*ISL1* regulates a large number of cell cycle-associated genes and genes of distinct oncogenic pathways required for neuroblastoma proliferation (*LMO1, LIN28B, AURKA, BARD1, CTBP2* and *MYB*). Consistent with this, knockdown of *ISL1* in neuroblastoma cells results in impaired proliferation and tumor growth. Furthermore, *ISL1* promotes neuroblastoma migration by directly regulating expression of genes involved in ECM assembly and metastasis, such as *LOX, LUM, MMP2* and*LMO1*. *LMO1* has been shown to promote neuroblastoma migration and metastasis by regulating expression of *LOXL3*, a member of the lysyl oxidase (*LOX*) family required for ECM formation and tumor metastasis [@B17], [@B49].

It is worth noting that, despite functional similarities in its role in sympathetic neuron and neuroblastoma, genes downstream of *ISL1* vary between different cell types. For instance, in sympathetic neurons, *ISL1* controls the cell cycle in part by regulating expression of D-type cyclins (early G1/S), whereas in neuroblastoma, by targeting members of E- and B- cyclins (late G1/S and M phase), *MYC* and *CDKN1A* [@B28]. Notably, *ISL1* is expressed in multiple tissues and cell types during development, e.g. cardiac cells, central neurons and pancreatic beta-cells, wherein it plays distinct roles in each of the cell types by regulating distinct genes and pathways [@B34], [@B50]-[@B55]. In addition, involvement of *ISL1* in several other cancer types has been reported, in which*ISL1* is required for proliferation via distinct mechanisms. These data have suggested context-dependent roles for *ISL1* during development and tumorigenesis.

*GATA3* is a key component of the gene regulatory program controlling early sympathetic neurogenesis [@B19]. Expression of *GATA3* is downregulated in *ISL1* knockout sympathetic neurons where *GATA3* is a direct target of *ISL1* [@B28]. However in neuroblastoma cells, expression of *GATA3* is not altered by*ISL1* knockdown, and vice versa. *GATA3* is overexpressed in neuroblastoma and is required for neuroblastoma proliferation and tumor growth [@B22]. Previous study has shown that GATA3 binds to *LMO1* super-enhancer driving its expression and neuroblastoma tumorigenesis [@B23]. Motif analyses of ISL1 ChIP-seq datasets from sympathetic neuron [@B28] and neuroblastoma suggest that *ISL1* and *GATA3* may collaborate to regulate common gene expression. Comparison of ChIP-seq datasets for ISL1 and GATA3 [@B23] in neuroblastoma cells has revealed a substantial overlap of the enhancers bound by ISL1 and GATA3. ISL1 and GATA3 synergistically bind to and regulate expression of genes essential for neuroblastoma tumorigenesis, such as *LMO1*, *CTBP2*, RA receptors and *CDKN1A*. Although DNA binding and transcriptional function of ISL1 is less dependent on the presence of GATA3, robust gene activation requires both ISL1 and GATA3.

Retinoic acids are widely used in neuroblastoma therapy, acting by promoting differentiation but repressing proliferation of neuroblastoma cells [@B56]. We found that *ISL1* represses RA signaling pathway by directly binding to and repressing expression of RA receptors (*RARA, RXRA* and *RORA*). Therefore, knockdown of *ISL1* in SH-SY5Y cells may de-repress RA receptors and sensitize neuroblastoma cells to RA signaling and enhance RA-induced differentiation. On the other hand, RA treatment has shown to repress expression of*ISL1* and *GATA3* and induces neuroblastoma differentiation [@B22], [@B41]. Together, these studies suggest that RA may modulate neuroblastoma proliferation and differentiation through a RA-triggered de-repression mechanism involving ISL1/GATA3 complex.

*MYCN* amplification is the most common genetic alteration in human neuroblastoma and a major cause of RA-resistance. During sympathetic neurogenesis, *MYCN* plays crucial roles in maintaining pluripotency and expansion of sympathetic progenitor cells, but blocking their differentiation [@B57]. Overexpression of *MYCN* leads to increased number of sympathetic progenitors and is sufficient to drive neuroblastoma tumorigenesis. Consistent with its role in sympathetic progenitors, expression of *MYCN* is largely confine to sympathetic progenitor cells and it is downregulated with sympathetic differentiation [@B58], [@B59]. In contrast, *ISL1* is expressed in sympathetic neurons immediately after their differentiation, but not in neural crest or sympathetic progenitor cells [@B28], suggesting that *MYCN* and *ISL1* may acts as temporal factors in distinct regulatory networks required for sequential events of sympathetic neurogenesis.

Similarly, in SK-N-BE(2) and SH-SY5Y neuroblastoma, *MYCN* expression is not altered by *ISL1* knockdown and vice versa. Expression of *LMO1* and *LIN28B*, the key genes downstream of *ISL1*, is not altered by *MYCN* knockdown in SK-N-BE(2) cells, suggesting distinct pathways regulated by *ISL1* and *MYCN* in *MYCN*-amplified neuroblastoma. Consistent with this, comparison of our ISL1 ChIP-seq and published MYCN ChIP-seq datasets in neuroblastoma [@B48] has revealed substantial divergences in the key downstream targets between *ISL1* and *MYCN*.

*ISL1* and *MYCN* play redundant roles in control of neuroblastoma proliferation and differentiation, at least in part, by regulating genes involved in the cell cycle and RA pathway. Similar to that observed in *ISL1* KD SH-SY5Y cells, knockdown of *MYCN* in SK-N-BE(2) cells leads to alterations in expression of cell cycle-related genes (e.g. *CCNE1, AURKA, PCNA, BARD1* and *CDKN1A*). However, *MYCN* amplification in SK-N-BE(2) cells prevents alterations in some of these cell cycle gene expression caused by *ISL1* knockdown. Furthermore, *ISL1* knockdown causes de-repression of RA receptors and their downstream genes in SH-SY5Y cells that, however, is significantly compromised by *MYCN* amplification in SK-N-BE(2) cells. Consequently, knockdown of *ISL1* in *MYCN* amplified SK-N-BE(2) cells failed to enhance neurite outgrowth by RA treatment. In contrast to the rather subtle changes in mRNA expression of RA receptors in *MYCN* KD SK-N-BE(2) cells, neurite outgrowth without RA treatment is significantly increased and that is further enhanced by RA treatment. Concomitant knockdown of *ISL1* and *MYCN* leads to a significant increase in RA-induced neurite outgrowth. These data suggest that *MYCN* suppresses neuroblastoma differentiation (neurite outgrowth) by RA-dependent and independent mechanisms.

In conclusion, our studies have revealed a complex gene regulatory network underlying neuroblastoma pathogenesis, in which *ISL1*, complexed with *GATA3*, acts as a key upstream regulator. *ISL1* and *MYCN* function in parallel to control common yet distinct oncogenic pathways required for neuroblastoma proliferation and differentiation. Other genetic and epigenetic factors, such as *ALK*, *LMO1*, *TGFβ* signaling and *H3K27* demethylation may collaborate with *MYCN*-amplification to confer high-risk and presumably RA-resistance phenotypes [@B17], [@B41], [@B60], [@B61]. Thus Combination therapies co-targeting these factors may provide a new therapeutic strategy for *MYCN* amplified and RA-resistant neuroblastoma.
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![**Knockdown of *ISL1* results in inhibition of neuroblastoma growth.** (A, B) Validation of shRNA-mediated knockdown *ISL1* by qPCR and Western blot (Arrow head) in SH-SY5Y cells. Error bars represent standard deviation (±SD), n=3, \*p\<0.05, \*\*p\<0.01, 2-tailed t-test. (C, D) Knockdown of *ISL1* with sh*ISL1-1* and sh*ISL1-2* results in inhibition of cell expansion in both SH-SY5Y and SK-N-BE(2) neuroblastoma cells. Error bars represent ±SD, n=6, \*p\<0.05, \*\*p\<0.01, 2-tailed t-test). (E) EdU staining of *ISL1* KD and control SH-SY5Y cells. (F) Quantification of EdU-positive cell percentage. Error bars represent ±SD; \*\* p\<0.01, n=5, 2-tailed t-test. (G) Flow cytometric analysis of EdU-positive cells in *ISL1* KD and control SH-SY5Y cells. (H, I) Colony formation of *ISL1* KD and control SH-SY5Y cells. Quantification of the total number of colonies in *ISL1* KD and control cultures. Error bars represent ±SD; n=4, \*\* p\<0.01, 2-tailed t-test. (J, K) Tumor formation following subcutaneous injection of *ISL1* KD and control SH-SY5Y cells. Images of SH-SY5Y-derived tumors presented (J), and tumor volume size monitored at indicated days post-injection (K). Error bars represent ±SD; n=3; \*p\<0.05, \*\*p\<0.01, 2-tailed t-test.](thnov09p0986g001){#F1}

![**Essential role of *ISL1* in regulating genes required for neuroblastoma pathogenesis.** (A) Scatterplot of RNA-seq showing relative gene expression of mRNA in *ISL1* KD and control SH-SY5Y cells. Red and blue represent genes upregulated or downregulated, respectively. (B, C) Gene Ontology (GO) functional clustering of genes down- and upregulated in *ISL1* KD SH-SY5Y cells, highlighting pathways most significantly affected in *ISL1* KD neuroblastoma cells (top 10 categories are shown). (D-F) Gene Set Enrichment Analysis (GSEA) showing downregulation of genesets involved in cell proliferation, DNA replication and mitotic nuclear division in *ISL1* KD SH-SY5Y cells. (G. H) qPCR validation of selected downregulated and upregulated genes in *ISL1* KD neuroblastoma, respectively Error bars represent ±SD, n=3 per group, \*p\<0.05; \*\*p\<0.01; 2-tailed t-test). (I-K) Increased RA-induced neurite outgrowth in *ISL1* KD neuroblastoma cells. All images were taken at 72 hours after RA or DMSO treatment. The extended neurites were stained with *TUJ1*. (M) Quantification of the length of neurites. The images from three biological replicates were pooled, and the length of longest neurite of individual cells was measured. The number of measured cells (n) per treatment group is 100. (\*p\<0.05; \*\*p\<0.01; 2-tailed t-test). (N-P) Transwell migration assay showing significantly reduced invasion and migration of *ISL1* KD cells compared to control cells. The cells that have migrated through the membrane are stained and counted (P). Error bars represent ±SD, n=5 per group, \*p\<0.05; \*\*p\<0.01; 2-tailed t-test).](thnov09p0986g002){#F2}

![***ISL1* directly regulates genes involved in neuroblastoma proliferation and differentiation.** (A) Genome-wide distribution of ISL1 ChIP-Seq peaks mapped relative to their nearest TSS (transcription start site). Annotation indicates the positions of peaks are in TTS (transcription termination site, defined as from -100bp to +1Kb), exon, 5\'UTR, 3\'UTR, intronic or intergenic. (B) Top motifs enriched in ISL1-bound regions. (C) GO analysis of genes associated with ISL1 ChIP-seq peaks (top 10 categories are shown). (D) Intersection of ISL1 ChIP-seq and *ISL1* KD RNA-seq datasets revealed 389 direct downstream targets of *ISL1* (186 upregulated and 203 downregulated) in neuroblastoma (DEG: differentially expressed genes). (E, F) Enriched GO terms of direct targets of *ISL1* downregulated (E) and upregulated (F) in neuroblastoma (top 10 categories are shown). (G) Integrative Genomics Viewer (IGV) showing ChIP-seq tracks for H3K4me1, H3K27ac, and ISL1 at the loci of representative *ISL1* target genes in neuroblastoma (arrowhead showing binding peaks).](thnov09p0986g003){#F3}

![***LMO1* is a direct downstream target of *ISL1* in neuroblastoma.** (A) ChIP-qPCR showing binding of ISL1 at P1, P2 and P3 enhancer regions of *LMO1*. Error bars represent ±SD; n=3, \*\*p\<0.01, 2-tailed t-test. (B) Luciferase assay showing *LMO1* superenhancer activity in the presence of*ISL1*. Error bars represent ±SD; n=3, \*\*p\<0.01, 2-tailed t-test. (C) Re-expression of *LMO1* partially restores cell growth of *ISL1* KD neuroblastoma cells. Error bars represent ±SD, n=6, \*p\<0.05; \*\*p\<0.01; 2-tailed t-test). (D) EdU staining showing re-expression of *LMO1* partially restores proliferation of *ISL1* KD neuroblastoma cells. (E) Quantification of EdU-positive cells. Error bars represent ±SD, n=5, \*p\<0.05; \*\*p\<0.01. (G) qPCR showing restored proliferation gene expression. Error bars represent ±SD, n=3, \*p\<0.05; \*\*p\<0.01, 2-tailed t-test).](thnov09p0986g004){#F4}

![***ISL1* and *Gata3* synergistically activate downstream genes in neuroblastoma.** (A. B) Heatmap (A) and aggregation plot (B) of ChIP-Seq mapped reads of Gata3 and ISL1 at all ISL1 binding sites. (C) Overlay of ISL1 ChIP-seq and GATA3 ChIP-seq datasets in SH-SY5Y (left). Overlay of the common target genes of *ISL1* and *GATA3* with genes differentially expressed in *ISL1* KD neuroblastoma cells. (right). (D) GO terms enriched in common direct targets of *ISL1* and *GATA3* upregulated or downregulated in *ISL1* KD neuroblastoma (top 5 not redundant categories are shown). (E) Integrative Genomics Viewer (IGV) showing ChIP-seq tracks for ISL1 and GATA3 at the loci of representative common target genes in neuroblastoma (arrowhead showing binding peaks). (F) qPCR analysis of *GATA3* KD SH-SY5Y cells, showing similar alterations in expression of selected *ISL1* target genes, noting that *ISL1* expression is not altered. Error bars represent ±SD, n=3, \*p\<0.05; \*\*p\<0.01, 2-tailed t-test. (G)*LMO1* enhancer Luciferase analysis in the presence of *ISL1* and/or*GATA3*. Error bars represent ±SD, n=3, \*\*p\<0.01, 2-tailed t-test). (H) *LMO1* mRNA expression in 293T cells transfected with *ISL1* and/or *GATA3*. Error bars represent ±SD; n=3; \*p\<0.05, \*\*p\<0.01, 2-tailed t-test. (I, J) GATA3 ChIP-qPCR analysis of *ISL1* KD neuroblastoma cells (I) and ISL1 ChIP-qPCR of *GATA3* KD neuroblastoma cells (J) on selected common targets of *ISL1* and *GATA3*. Error bars represent ±SD; n=3; \*p\<0.05, \*\*p\<0.01, 2-tailed t-test.](thnov09p0986g005){#F5}

![***ISL1* and *MYCN* act in parallel to regulate common yet distinct oncogenic pathways in neuroblastoma.** (A, B) Relative mRNA expression of *ISL1, MYCN, GATA3* and selected *ISL1* or *MYCN* downstream genes in *ISL1* KD and *MYCN* KD SK-N-BE(2) neuroblastoma cells. Error bars represent ±SD; n=3; \*p\<0.05, \*\*p\<0.01, 2-tailed t-test. (C-G) EdU staining of control, *ISL1* KD, *MYCN* KD and *MYCN/ISL1* double-KD SK-N-BE(2) cells, and quantification of EdU-positive cells. Error bars represent ±SD; \*\* p\<0.01, n=5, 2-tailed t-test. (H-P) neurite outgrowth of *ISL1* KD, *MYCN* KD, *ISL1/MYCN*-double KD and control SK-N-BE(2) cells with or without RA. All images were taken at 72 hours after RA or DMSO treatment. The images from three biological replicates were pooled, and the length of longest neurite of individual cells was measured (P). In RA untreated groups, the number of measured cells (n) in Ctrl, *ISL1* KD, *MYCN* KD and *ISL1/MYCN* double-KD group is 100, 98, 95 and 95, respectively. In RA treated groups, the number of measured cells (n) in Ctrl, *ISL1* KD, *MYCN* KD and *ISL1/MYCN* double-KD group is 105, 121, 96 and 95, respectively. (\*p\<0.05; \*\*p\<0.01; 2-tailed t-test). (Q) The regulatory network controlling neuroblastoma pathogenesis.*ISL1*, together with *GATA3*, acts upstream of multiple oncogenic pathway essential for neuroblastoma proliferation and differentiation. In *MYCN*-amplified SK-N-BE(2) neuroblastoma cells, *MYCN* acts in parallel with *ISL1* to control the cell cycle and RA-mediated differentiation. In addition, *MYCN* can suppress differentiation (neurite outgrowth) independent of RA pathways.](thnov09p0986g006){#F6}
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